Reports Q3 revenue $1.45B, consensus $1.45B. “We are pleased with our third quarter performance,” stated CEO Marty Bonick. “Year-over-year growth in key metrics, including inpatient and outpatient surgeries and admissions, accelerated compared to the first half of 2024. Net income attributable to Ardent Health (ARDT) increased to $26M and adjusted EBITDA improved 15% year-over-year with margins expanding 50bps to 6.7%…Our solid Q3 results, coupled with momentum from our strategic execution, give us confidence to increase our 2024 adjusted EBITDA guidance midpoint by 2% and modestly improve our revenue outlook”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- BofA shakes up ratings of healthcare stocks following Trump win
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Ardent Health downgraded to Neutral at BofA after Trump win
- Ardent Health downgraded to Neutral from Buy at BofA
- Ardent Health initiated with an Overweight at KeyBanc